-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFI-003 in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AFI-003 in Pain Drug Details:AFI-003 is under development for the treatment of severe pain. The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFI-002 in Attention Deficit Hyperactivity Disorder (ADHD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AFI-002 in Attention Deficit Hyperactivity Disorder (ADHD) Drug Details:AFI-002 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KRLS-004 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KRLS-004 in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KRLS-004 in Renal Cell Carcinoma Drug Details: KRLS-004 (ASN-004) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talimogene Laherparepvec in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talimogene Laherparepvec in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenalidomide in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenalidomide in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenalidomide in Relapsed Multiple Myeloma Drug Details: Lenalidomide (Revlimid) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IPH-5301 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPH-5301 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IPH-5301 in Solid Tumor Drug Details:IPH-5301 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelcitoclax in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelcitoclax in Natural Killer Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pelcitoclax in Natural Killer Cell Lymphomas Drug Details:Pelcitoclax (APG-1252) is under...
-
Product Insights
AFI Dev – Afi Tower Residential Complex – Moscow
Equip yourself with the essential tools needed to make informed and profitable decisions with our AFI Dev - Afi Tower Residential Complex - Moscow report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
AFI Dev – AFI Park Vorontsovsky Multifunctional Complex – Moscow
Equip yourself with the essential tools needed to make informed and profitable decisions with our AFI Dev - AFI Park Vorontsovsky Multifunctional Complex - Moscow report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
AFI Dev – Silver Multifunctional Residential Complex – Moscow
Equip yourself with the essential tools needed to make informed and profitable decisions with our AFI Dev - Silver Multifunctional Residential Complex - Moscow report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...